In a dose-dependent manner, TGF-β or, alternatively, ginsenosides Rk1 and Rg5 treatment in NSCLC A549 cells, regulate EMT by suppressing the Smad and NF-kB/ERK pathways (non-Smad pathway) [42]. Here, MAPK1 is linked to non-small cell lung carcinoma.